Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-08
2008-07-08
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S224000, C548S300100, C548S302700, C546S268100, C514S361000, C514S277000, C514S314000
Reexamination Certificate
active
11345987
ABSTRACT:
Tertiary amine compounds that bind chemokine receptors such as CXCR4 and CCR5 are disclosed.
REFERENCES:
patent: 5021409 (1991-06-01), Murrer et al.
patent: 5583131 (1996-12-01), Bridger et al.
patent: 5698546 (1997-12-01), Bridger et al.
patent: 5817807 (1998-10-01), Bridger et al.
patent: 6001826 (1999-12-01), Murrer et al.
patent: 6750348 (2004-06-01), Bridger et al.
patent: 6864265 (2005-03-01), Bridger et al.
patent: 1 163 238 (2001-12-01), None
patent: WO-99/38514 (1999-08-01), None
patent: WO-00/42852 (2000-07-01), None
patent: WO-00/51607 (2000-09-01), None
patent: WO-00/56729 (2000-09-01), None
patent: WO-02/22599 (2002-03-01), None
patent: WO-02/22600 (2002-03-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
U.S. Appl. No. 60/172,153 filed by Bridger et al. on Dec. 17, 1999.
U.S. Appl. No. 09/111,895 filed by Bridger et al. on Jul. 8, 1998.
U.S. Appl. No. 09/495,298 filed by MacFarland et al. on Feb. 1, 2000.
U.S. Appl. No. 09/535,314 filed by Bridger et al. on Mar. 24, 2000.
Abi-Younes et al. (2000).Circ. Res.86:131-138.
Alkhatib et al. (1996).Science272:1955-1958.
Arai et al. (2000).Eur. J. Haematol.64:323-332.
Arenburg et al. (1997).J. Leukocyte Biol.62:554-562.
Auiti et al. (1997).J. Exp. Med.185:111-120.
Baggiolini, M. (1998).Nature392:565-568.
Bajetto et al. (1999).J. Neurochem.73:2348-2357.
Berger et al. (1999).Annu Rev. Immunol.17:657-700.
Biard-Piechaczyk et al. (2000).Virology268:329-344.
Blaak et al. (2000).Proc. Natl. Acad. Sci.97:1269-1274.
Blanco et al. (2000).Antimigrobial Agents and Chemother44:51-56.
Bleul et al. (1998).J. Exp. Med.187:753-762.
Bleul et al. (1996).Nature382:829-833.
Bradstock et al. (2000).Leukemia14:882-888.
Bridger et al. (1999). “Bicyclam Derivatives as HIV Inhibitors” inAdvances in Antiviral Drug Design.vol. 3., JAI press., pp. 161-229.
Bridger et al. (1999).J. Med. Chem.42:3971-3981.
Burger et al. (1999).Blood94:3658-3667.
Buttini et al. (1998).Nature Med.4:441-446.
Carroll et al. (1997).Science276:273-276.
Cocchi et al. (1995).Science270: 1811-1815.
Connor, R.I., Ho, D.D. (1994).J. Virol.68:4400-4408.
Database WPI AN209951, XP002189031.
Deng et al. (1996).Nature381:661-666.
Donzella et al. (1998).Nature Medicine4:72-77.
Dragic et al. (1996).Nature381:667-673.
Egberink et al. (1999).J. Virol.73:6346-6352.
Eitner et al. (1998).Transplantation66:1551-1557.
Fedyk et al. (1999).J. Leukocyte Biol.66:667-673.
Feng et al. (1996).Science272:872-877.
Gonzalo et al. (2000).J.Immunol.165:499-508.
Gupta et al. (1998).J.Biol. Chem.7:4282-4287.
Herbein et al. (1998).Nature395:189-194.
Hesselgesser et al. (1999). “Chemokines and Chemokine receptors in the Brain” inChemokines in Disease,Humana Press, pp. 295-312.
Hesselgesser et al. (1997).Curr. Biol.7:112-121.
Hesselgesser et al. (1998).Curr. Biol.8:595-598.
Ishii et al. (1999).J.Immunol.163:3612-3620.
Lataillade et al. (2000).Blood95:756-768.
Liu et al. (1996).Cell86:367-377.
Locati et al. (1999).Annu. Rev. Med.50:425-40.
Maekawa et al. (2000).Internal Medicine39:90-100.
Michael et al. (1997).Nature Med.3:338-340.
Michael et al. (1998).J. Virol.72:6040-6047.
Miedema et al. (1994).Immune. Rev.140:35-72.
Moore et al. (1998).J. Invest. Med.46:113-120.
Moore et al. (1998).Trends Cardiovasc. Med.8:51-58.
Murdoch et al. (2000).Blood95:3032-3043.
Nagasawa et al. (1996).Nature382:635-638.
Nagase, et al. (2000).J. Immunol164:5935-5943.
Nanki et al. (2000).J. Immunol164:5010-5014.
Oberlin et al. (1996).Nature382:833-835.
O'Brien et al. (1997).Lancet349:1219.
Ohagen et al. (1999).J. Virol.73(2):897-906.
Peled et al. (2000).Blood95(11):3289-3296.
Peled et al. (1999).Science283:845-848.
Ponath, P. (1998).Exp. Opin. Invest. Drugs7(1):1-18.
Qing et al. (1999).Immunity10:463-471.
Rana et al. (1997).J. Virol.71:3219-3227.
Rizzuto et al. (1998).Science280:1949-1953.
Salcedo et al. (1999).Am. J. Pathol.154(4):1125-1135.
Samson et al. (1996).Nature382:722-725.
Sanders et al. (2000).J. Neuroscience Res.59:671-679.
Schols et al. (1997).Antiviral Research35:147-156.
Schols et al. (1997).J. Exp. Med.186(8):1383-1388.
Schuitemaker et al. (1992).J. Virol.66:1354-1360.
Seghal et al. (1998).J. Surg. Oncol.69:99-104.
Simmons et al. (1969).J. Virol.70(12):8355-8360.
Simmons et al. (1988).J. Virol.72(10):8453-8457.
Tachibana et al. (1998).Nature393:591-594.
Tersmette et al. (1988).J. Virol.62(6):2026-2032.
Theodorou et al. (1997).Lancet349:1219-1220.
Viardot et al. (1998).Ann. Hematol.77:193-197.
Volin et al (1998).Biochem. Biophys Res. Commun.242:46-53.
Wyatt et al. (1998).Science280:1884-1888.
Xia et al. (1999).J. NeuroVirology5:32-41.
Yssel et al. (1998).Clinical and Experimental Allergy28:104-109.
Zhang et al. (1997).AIDS Res. Hum. Retroviruses13(16):1357-1366.
Zhang et al. (1998).J. Virol.72:9307-9312.
Zhang et al. (1999).J. Virol.73(4):3443-3448.
Zhang et al. (1999).J. Virol.73(10):8256-8267.
Atsma Bern
Bogucki David
Bridger Gary
Crawford Jason
Di Fluri Maria Rosaria
Desai Rita J
Genzyme Corporation
Morrison & Foerster / LLP
LandOfFree
Chemokine receptor binding heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemokine receptor binding heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokine receptor binding heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3928162